mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy

BACKGROUND: Tyrosine kinase inhibitors (TKIs) that act against the epithelial growth factor receptor (EGFR) were once widely used in chemotherapy for many human cancers. However, acquired chemoresistance occurred in almost all patients, limiting the clinical application of EGFR-TKI. Thus far, no eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yan, Su, Chang, Zhao, Liang, Shi, Yijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628454/
https://www.ncbi.nlm.nih.gov/pubmed/28978341
http://dx.doi.org/10.1186/s12951-017-0302-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628454/
https://www.ncbi.nlm.nih.gov/pubmed/28978341
http://dx.doi.org/10.1186/s12951-017-0302-5

Ejemplares similares